pravastatin has been researched along with Cancer of Liver in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Draper, CD; Hutson, JL; Inglis, GG; Procopiou, PA; Ross, BC; Watson, NS | 1 |
| Abdelghani, MB; Audemar, F; Blanc, JF; Bourgeois, V; Bronowicki, JP; Costentin, C; Deplanque, G; Edeline, J; Faroux, R; Khemissa, F; Locher, C; Mabile-Archambeaud, I; Manfredi, S; Monterymard, C; Obled, S; Perarnau, JM; Seitz, JF; Senellart, H; Villing, AL | 1 |
| Barbier, E; Bouché, O; Bronowicki, JP; Debette-Gratien, M; Denis, J; Faroux, R; Jouve, JL; Khemissa Akouz, F; Lecomte, T; Legoux, JL; Manfredi, S; Nguyen Khac, E; Ollivier-Hourmand, I; Phelip, JM; Ramee, JF; Riachi, G; Seitz, JF; Vergniol, J; Villing, AL | 1 |
| Byun, HW; Choi, MH; Hong, EM; Jang, HJ; Kae, SH; Koh, DH; Lee, J; Park, SH | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Dogan, S; Goke, B; Graf, H; Helmberger, T; Hoffmann, RT; Jakobs, T; Jüngst, C; Jüngst, D; Reiser, M; Seidel, D; Straub, G; Waggershauser, T; Walli, A; Walter, A | 1 |
| Furukubo, T; Hatozaki, D; Izumi, S; Minegaki, T; Nishiguchi, K; Shima, D; Tsujimoto, M; Yamakawa, T; Yokota, H | 1 |
| Blum, HE; Spangenberg, HC; Thimme, R; Von Weizsäcker, F; Zuber-Jerger, I | 1 |
| Crisby, M; Högberg, J; Pääjärvi, G; Roudier, E; Stenius, U | 1 |
| Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR | 1 |
| Mistafa, O; Roudier, E; Stenius, U | 1 |
| Funakoshi, A; Kono, A; Shimazoe, T | 1 |
| Ishiguro, H; Kawata, S; Matsuzawa, Y; Nagase, T; Yamasaki, E | 1 |
| Abe, K; Goto, D; Kuwano, M; Okimoto, T; Ono, M; Shimotsu, H; Tsujita, Y | 1 |
| Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E | 1 |
| Aldaghlas, TA; Berthold, HK; Holleran, AL; Kelleher, JK; Lindenthal, B; Sudhop, T; Von Bergmann, K | 1 |
| Imanaka, T; Sato, R; Takano, T | 1 |
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
2 review(s) available for pravastatin and Cancer of Liver
| Article | Year |
|---|---|
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
[Systemic treatment for hepatocellular carcinoma].
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cyclohexanes; Disease Models, Animal; Genetic Therapy; Humans; Immunotherapy; Liver Neoplasms; Meta-Analysis as Topic; Mice; Multicenter Studies as Topic; O-(Chloroacetylcarbamoyl)fumagillol; Octreotide; Pilot Projects; Pravastatin; Primary Prevention; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Sesquiterpenes; Tamoxifen; Thymus Extracts; Time Factors | 2003 |
4 trial(s) available for pravastatin and Cancer of Liver
| Article | Year |
|---|---|
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pravastatin; Prospective Studies; Sorafenib; Treatment Outcome | 2021 |
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pravastatin; Prognosis; Progression-Free Survival; Quality of Life; Sorafenib | 2019 |
Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Epirubicin; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pravastatin; Prospective Studies | 2008 |
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Hepatocellular; Drug Administration Schedule; Embolization, Therapeutic; Female; Fluorouracil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Male; Middle Aged; Pravastatin | 2001 |
12 other study(ies) available for pravastatin and Cancer of Liver
| Article | Year |
|---|---|
Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Topics: Carcinoma, Hepatocellular; Cholesterol; Humans; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Pravastatin activates the expression of farnesoid X receptor and liver X receptor alpha in Hep3B cells.
Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Cholesterol 7-alpha-Hydroxylase; Hepatocytes; Humans; Lipoproteins; Liver Neoplasms; Liver X Receptors; Orphan Nuclear Receptors; PPAR alpha; PPAR gamma; Pravastatin; Receptors, Cytoplasmic and Nuclear; RNA, Messenger | 2014 |
Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.
Topics: Biological Transport; Caco-2 Cells; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Kidney Failure, Chronic; Liver; Liver Neoplasms; Liver-Specific Organic Anion Transporter 1; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Renal Dialysis; RNA, Messenger; Uremia | 2012 |
HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Enzyme Inhibitors; Female; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Insulin; Liver; Liver Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pravastatin; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2005 |
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor | 2005 |
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinoma, Hepatocellular; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Etoposide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Morpholines; Phosphorylation; Pravastatin; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2006 |
[Effect of 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitor, pravastatin on liver metastasis of a pancreatic cancer cell line, SUIT-2 in nude mice].
Topics: Animals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Pravastatin | 1994 |
Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2).
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cell Line; Cholesterol; Cyclohexenes; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Interactions; Humans; Kinetics; Limonene; Liver Neoplasms; Mevalonic Acid; Pravastatin; Protein Prenylation; Proto-Oncogene Proteins p21(ras); Terpenes; Tumor Cells, Cultured | 1994 |
Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts.
Topics: Carcinoma, Hepatocellular; Dactinomycin; ErbB Receptors; Gemfibrozil; Gene Expression Regulation, Neoplastic; Genes, Reporter; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Neoplasms; Mevalonic Acid; Neoplasm Proteins; Pravastatin; Promoter Regions, Genetic; Receptors, LDL; RNA, Messenger; RNA, Neoplasm; Transfection; Tumor Cells, Cultured; Up-Regulation | 1997 |
Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells.
Topics: Acetates; Acetyl Coenzyme A; Carbon Isotopes; Carcinoma, Hepatocellular; Cholesterol; Duodenum; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isotope Labeling; Kinetics; Liver; Liver Neoplasms; Models, Biological; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma Hep G2.
Topics: Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Carcinoma, Hepatocellular; Cholesterol; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Liver Neoplasms; Naphthalenes; Pravastatin; Tumor Cells, Cultured; Ultracentrifugation | 1990 |
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |